Your browser doesn't support javascript.
loading
Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion.
Serhan, Habib A; Bao, Liwei; Cheng, Xu; Qin, Zhaoping; Liu, Chia-Jen; Heth, Jason A; Udager, Aaron M; Soellner, Matthew B; Merajver, Sofia D; Morikawa, Aki; Merrill, Nathan M.
Afiliación
  • Serhan HA; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Bao L; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Cheng X; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Qin Z; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Liu CJ; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Heth JA; Department of Neurosurgery, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Udager AM; Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Soellner MB; Department of Chemistry, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Merajver SD; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Morikawa A; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Merrill NM; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA. nmerrill@umich.edu.
NPJ Breast Cancer ; 10(1): 43, 2024 Jun 10.
Article en En | MEDLINE | ID: mdl-38858374
ABSTRACT
Fatty acid synthesis (FAS) has been shown to play a key role in the survival of brain-metastatic (BM) breast cancer. We demonstrate that the fatty acid synthase inhibitor TVB-2640 synergizes with the topoisomerase inhibitor SN-38 in triple-negative breast cancer (TNBC) BM cell lines, upregulates FAS and downregulates cell cycle progression gene expression, and slows the motility of TNBC BM cell lines. The combination of SN-38 and TVB-2640 warrants further consideration as a potential therapeutic option in TNBC BMs.